Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study of Romosozumab in People With Breast Cancer and Osteoporosis

ClinicalTrials.gov ID: NCT07776613

Public ClinicalTrials.gov record NCT07776613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Aug 21, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study Evaluating the Efficacy and Safety of Romosozumab as a Bone-Modifying Agent in Patients With Metastatic Breast Cancer to Bones and Osteoporosis With High Fracture Risk (REMOLD-Breast)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The researchers are doing this study to see if romosozumab is effective at helping with bone formation in people with metastatic breast cancer (MBC) that has spread to the bones. All participants will have osteoporosis. The researchers will also look at bone breakdown (resorption) in participants and determine if romosozumab is a safe treatment for osteoporosis in people with MBC that has spread to the bones.

Study identification

NCT ID
NCT07776613
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
25 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 16, 2026
Primary completion
Jul 31, 2028
Completion
Jul 31, 2028
Last update posted
Aug 19, 2026

2026 – 2028

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey 07920 Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 Recruiting
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) Commack New York 11725 Recruiting
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 Recruiting
Memorial Sloan Kettering Cancer Center New York New York 10065 Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities) Uniondale New York 11553 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Breast Cancer trials

Other public records listing Breast Cancer. Sorted by last update posted; newest first. Not a recommendation.

All Breast Cancer trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07776613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2026 · Synced Aug 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07776613 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →